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Abstract 16 
New frontiers for host-microbe interactions continue to emerge as our knowledge of the adult gut 17 
microbiome in health and disease is continually supplemented and improved. Alterations in the gut 18 
microbiota composition in irritable bowel syndrome (IBS) are now linked to symptom severity 19 
while population based evidence linking gut microbiome signatures to depression is an important 20 
new landmark. The effects of drugs on gut microbiome composition is also becoming clearer.  21 
Meanwhile, preclinical studies have delineated the influence of the gut microbiome at a structural 22 
and activity level in distinct brain regions. Bacterial metabolites, such as tryptamine, can activate 23 
specific receptors to impact gastrointestinal motility. These recent studies bring into focus the 24 
future implications for therapeutic targeting of the microbiome-gut-brain axis. 25 
 26 
  27 
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Introduction 28 
As our knowledge of the important role played by the gut microbiota in health and disease expands, 29 
new frontiers for host-microbe interactions continue to emerge. Recently, traditional concepts in 30 
pharmacology and therapeutics have been challenged by reports outlining reciprocal microbiome-31 
xenobiotic interactions and a growing appreciation that microbial metabolites might exert their 32 
effects via receptor-mediated mechanisms. In this review, we first outline the most salient aspects 33 
of the composition and function of the gut microbiome as a framework to understand the 34 
importance of this virtual organ for gastrointestinal pharmacology and beyond. We then focus on 35 
a number of key recently published articles illustrating the implications of important conceptual 36 
advances that chart the scope and scale of microbial regulation of pharmacodynamics and 37 
pharmacokinetics in the gut-brain axis. This is considered within the context of the bidirectional 38 
relationship between xenobiotics and our gut bacteria. Finally, we attempt to integrate these 39 
observations to elaborate on the future implications for therapeutic targeting of the microbiome-40 
gut-brain axis.  41 
The Adult Gut Microbiome: A Metabolic Powerhouse 42 
The adult gut microbiota is made up of trillions of microorganisms (bacteria, viruses, archaea, 43 
yeasts and fungi) that reside in the gastrointestinal tract, contributing substantially to host 44 
physiological homestasis. The community of bacteria is best studied with the highest density in the 45 
large intestine which according to recent estimates reaches 1013 bacterial cells in the human colon 46 
[1,2]. The composition and function of this complex bacterial ecosystem is individual –specific 47 
and impacted by a number of intrinsic and extrinsic factors, including diseases and drug use, diet, 48 
age and lifestyle of the host [3-5]. Recent sequencing surveys confirm that the adult gut microbiota 49 
is dominated from a compositional perspective by the phyla Firmicutes, Actinobacteria and 50 
Bacteroidetes with lower relative abundances of Verrucomicrobia and Proteobacteria.  There may 51 
also be a core microbiota defined by 14 different genera with medication use in general contributing 52 
to microbiota compositional variation [3]. Our knowledge of the complexity of this virtual organ 53 
continues to expand and through the use of sequencing approaches, metagenomic analysis and 54 
bioinformatic pipelines. Pasolli and colleagues [6] have recently elegantly revealed the presence of 55 
new microbial species on or in the host, including the gut, associated with westernized or non-56 
westernized lifestyles. In addition, many newly identified species-level operational taxonomic 57 
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units (OTUs) may be associated with disease states as their genome sequences were not previously 58 
captured in databases [7]. 59 
The aggregate genome of this community, the metagenome, far exceeds and complements the 60 
metabolic capacity of the host genome. These microbial genes encode an array of metabolic 61 
activities, providing the host with additional essential functional capacity, such as the digestion of 62 
dietary fibers, which yields microbial metabolites important for host-microbe interactions. All 63 
these recent reports continue to support the importance of the gut microbiota in human health, 64 
although there remains knowledge gaps surrounding the precise composition of a healthy gut 65 
microbiome across the life span and more granular details on the molecular mechanisms 66 
underpinning complex host-microbe interactions, particularly in the context of gastrointestinal 67 
pharmacology.  68 
  69 
The Gut Microbiome in Disease 70 
Shifts in the bacterial composition, structure or function in the gastrointestinal tract have been 71 
associated with numerous disorders in the last few decades. As studies go beyond microbial 72 
surveys, the quality of the information derived from these studies continues to improve. For 73 
example, it now appears that alterations in the gut microbiota composition in irritable bowel 74 
syndrome (IBS) may include microbiota signatures associated with symptom severity [8]. In 75 
particular, IBS symptom severity was negatively associated with microbial richness as well as the 76 
presence of methanogens, and gut microbiota enterotypes characterized by enriched Clostridiales 77 
or Prevotella species [8]. This confirms the importance for the gut microbiota in the development 78 
of functional gastrointestinal disorders as well as chronic inflammatory diseases (see [9]).  79 
With the increasing number of studies focused on the gut microbiota and mental health, 80 
compositional alterations have also been highlighted in psychiatric and neurological disorders, such 81 
as Alzheimer’s disease [10], Parkinson’s disease [11,12], autism spectrum disorders (ASD) [13], 82 
schizophrenia [14] and depression [15]. In many cases, a causal role for these disease-associated 83 
microbiome configurations can be inferred from the transfer of behavioural phenotypes to animal 84 
models via the microbiota [15,16]. In the case of IBS, this even extends to the transfer of specific 85 
psychiatric comorbidities such as anxiety [16]. More recently, the analysis of a large microbiome 86 
population cohort enabled the identification of Dialister and Coprococcus spp as indicators of high 87 
quality of life, and revealed their depletion in depressive patients [17]. The results of this study 88 
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have advanced our knowledge further, providing the first population based evidence linking gut 89 
microbiome compositional signatures with a mental health disorder. It is therefore becoming 90 
increasingly important to consider the intestinal microbiota as a biomarker reservoir, in the 91 
development of new treatments and as a source of the side effects associated with particular host-92 
directed medications.  93 
 94 
--- Insert Figure 1 Here --- 95 
The Gut Microbiome and Expanding array of Therapeutic Targets in the Gut-brain Axis: 96 
While microbial signatures or alterations in the composition of the microbiota now appear to be 97 
evident in various pathologies, the extent of, and mechanisms involved in, this communication 98 
remain to be fully grasped. A variety of preclinical approaches, including the use of germ-free 99 
animals (GF), have allowed the scope of influence of the enteric microbiota on the brain-gut axis 100 
to be defined. Abdominal pain, underpinned by visceral hypersensitivity, is a core feature of 101 
irritable bowel syndrome (IBS). Recently, it has been conclusively demonstrated that the gut 102 
microbiota is required for normal visceral pain sensation, associated with increases in toll-like 103 
receptor and cytokine gene expression in the spinal cord. This study also demonstrated that the 104 
volumes of brain regions involved in pain processing such as the anterior cingulate cortex (ACC) 105 
and periaqueductal grey, were decreased and enlarged respectively in GF mice. [18]. This is 106 
consistent with previous studies which have demonstrated that the visceral hypersensitivity of IBS 107 
patients can be transferred to GF rats via the fecal microbiota [19]. 108 
Microbial regulation of the transcriptional activity in different brain areas, such as amygdala, 109 
prefrontal cortex or hippocampus, is now supported by several studies and often occurs in a sex-110 
dependent manner [20-22]. Studies in GF animals also now implicate the gut microbiome in 111 
appropriate regulation of microRNA (miRNAs; non coding RNAs that act through translational 112 
repression to control gene expression) expression in brain regions implicated in anxiety-like 113 
behaviours such as the amygdala and prefrontal cortex [22] or in memory and learning, such as the 114 
hippocampus [21,23]. For instance, in the absence of a gut microbiota, the basal expression of 115 
specific activity-related genes in the amygdala is altered, leading to the suggestion that a 116 
hyperactivity of this brain structure might be at the root of the behavioural abnormalities associated 117 
with growing up germ free [24-27]. Whether this can be exploited therapeutically is an open 118 
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question but in support of this possibility, the behavioural consequences as well as the molecular 119 
signature of his hyperactivity can at least partially be reversed by the colonization of GF animals  120 
[25].  Of further interest is that fecal miRNAs of host or plant origin may have an important role in 121 
dictating microbiota composition, possibly  by targeting regions in bacterial metagenomes [27-30] 122 
while fecal miRNA expression is also linked to gut microbiota fluctuations [31].  123 
A recent study, based on a mouse model of autism (BTBR mice), highlighted a significant decrease 124 
of two bile-metabolizing species: Bifidobacterium  and Blautia. Moreover, this compositional shift 125 
was associated with deficient bile acid and tryptophan metabolism, gastrointestinal dysfunction 126 
and impaired social interactions [32]. These results support the concept that modulation of the gut 127 
microbiota could be a promising strategy for the treatment of brain-gut axis disorders. In this 128 
context, Burokas and his team assessed the effect of the administration of two prebiotics in a rodent 129 
study: the gluco- and the fructo-oligosaccharides (GOS and FOS). Besides modifying the 130 
expression of genes such as BDNF in the hippocampus, GOS and FOS also exerted anxiolytic and 131 
antidepressant effects and reversed the behavioral and physiological impact of chronic stress 132 
exposure [33]. The finer details of the mechanisms mediating these beneficial effects remains 133 
unclear in many cases but substantial progress has been made in this area, particularly in the context 134 
of pharmacodynamic interactions between microbial metabolites and the host. 135 
The Gut Microbiome and Pharmacodynamics 136 
Bacterial metabolites are considered likely to be key mediators of these host microbe interactions 137 
with the possibility they can induce host cellular responses via their activity at G-protein-coupled 138 
receptors (GPCRs) expressed either locally in the gastrointestinal tract or at more distal locations 139 
[34]. One such example is tryptamine (a monoamine similar to 5-hydroxytryptamine (5-HT)), 140 
metabolized by bacteria via tryptophan decarboxylation, which modulate colonic secretion via 141 
activation of the 5-HT4 receptor (5-HT4R), a 5-HT receptor expressed in the colon of importance 142 
for regulation of gastrointestinal motility [35-37]. Another receptor of importance in this regard is 143 
the aryl hydrocarbon receptor (AhR) and a reduction of the microbiota’s ability to metabolize 144 
tryptophan into ligands capable of activating this has been identified in metabolic syndrome [38] 145 
and colitis [39], supporting the importance of this bacterial product in receptor-mediated host 146 
homeostasis.  147 
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In other cases, microbial metabolites may alter the expression of key receptors to influence 148 
gastrointestinal function. The most studied metabolites produced by gut bacteria are the short chain 149 
fatty acids (SCFAs), derived from the fermentation of dietary fibers. For example, acetate 150 
production can regulate the expression of 5-HT3 receptor expression to influence host secretory 151 
patterns [36]. Beyond intestinal-located interactions and although well known for their direct 152 
interactions with the free fatty acid receptor (FFAR) 2 and 3 in the regulation of appetite and energy 153 
intake, SCFA supplementation  has recently been associated with antidepressant and anxiolytic 154 
effects in mice. These effects were not present following exposure to a psychosocial stressor but 155 
the SCFA treatment did alleviate stress-induced increases in intestinal permeability while the 156 
stress-induced alterations in colonic gene expression of the SCFA receptors free fatty acid receptors 157 
were unaffected by SCFA supplementation  [40].  158 
The gut microbiota can also secrete compounds able to translocate from the gut to the systemic 159 
circulation, and to subsequently cross the blood-brain barrier. This applies to bacterial 160 
peptidoglycan (PGN), a major component of the bacterial membrane, which is able to activate 161 
neuronal pattern-recognition-receptors (PRR), leading to modulation of  brain development during 162 
specific time windows, through an interaction with Pglyrp2 [41]. A deeper understanding of the 163 
functional implications and regulation of bacterial-products could then constitute a relevant 164 
strategy for modulating host homeostasis, and potentially the development of new therapies in a 165 
wide range of gut-brain axis disorders.  166 
The Gut Microbiome, Pharmacokinetics and Toxicity 167 
The study of pharmacokinetics has traditionally focused on the impact of the host on administered 168 
drugs without due regard for the functional capacity of the gut microbiota. Orally administrated 169 
drugs in particular represent a potential substrate for bacterial metabolism, which can lead to 170 
intrapersonal variations in drug availability, efficacy or toxicity. One of the prospective drugs for 171 
such a transformation was the immunosuppressant mycophenolate mofetil (MMF), which, despite 172 
its effectiveness, induces significant side effects. Nevertheless, treating GF mice with MMF 173 
showed significantly reduced side effects [42], strongly implicating the gut microbiota in the 174 
emergent adverse effects.  175 
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The bacteria inhabiting our gut have at their disposal a range of microbial enzymes able to modify 176 
drugs and other xenobiotics. Tyrosine decarboxylase (TDC), expressed in particular by 177 
Enterococcus and Lactobacillus, was pointed out for its ability to interfere in the treatment of 178 
Parkinson’s disease through the inactivation of levodopa (L-DOPA) [43]. Moreover, it seems like 179 
prolonged treatment with L-DOPA enhances tdc gene expression, leading to a less and less 180 
effective treatment over time. F. Prauznitzii and Clostridiales, other specific enteric bacteria, have 181 
also been involved in the decrease of effectiveness of the immunosuppressant tacrolimus [44], 182 
highlighting the potential negative effect of gut microbiota on an orally administered medical 183 
treatment. In a similar vein, a bioinformatic approach enabled the identification of tyramine oxidase 184 
expressed by E. Coli as capable of binding amphetamine, leading to a potential modification of the 185 
drug [45]. Together, these results substantiate the relevance of using new models in pharmacology, 186 
that take into consideration microbial metabolism and the associated intra-individual variations. 187 
After an adaptation for other xenobiotics, the pharmacokinetic model built by Zimmermann and 188 
his team would hence represent an interesting basis to separate host and microbiome contributions 189 
to pharmacokinetics and toxicity [46].  190 
--- Insert Figure 2 Here --- 191 
Effects of drugs on the gut microbiome 192 
While, as shown above, the microbiota can have negative effects on the pharmacological properties 193 
of drugs, the reverse pattern is also valid: a large number of host-directed drugs across therapeutic 194 
classes combined, can affect the bacterial growth of at least 1 strain in vitro [47]. Psychotropic 195 
drugs have been particularly highlighted for their antimicrobial effects, causing alterations of the 196 
microbiota as well as modifications of gastrointestinal function such as intestinal permeability in 197 
vivo, and impacting on bacterial growth in vitro (Table 1) [48,49]. Earlier studies indicated that 198 
olanzapine altered the composition of the gut microbiota [50]. Further studies focusing on this drug 199 
showed that the microbiota was needed for drug-associated weight gain, a serious and common 200 
side effect of this antipsychotic treatment [51], as antibiotics attenuated the side effects in mice. 201 
This was also true in germ-free animals and olanzapine has antimicrobial effects on the growth of 202 
E. Coli and Enterococcus faecalis in vitro [52]. This opens up the possibility of targeting the gut 203 
microbiota with, for example, prebiotics to try and limit these adverse side effects [53].  204 
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Alternative approaches allowing the modulation of the enteric microbiota, such as  fecal microbiota 205 
transplant (FMT), might also lend themselves to counterbalance, or at least limit, these adverse 206 
effects or indeed promote beneficial effects. Interestingly, the ketogenic diet (KD) which is used 207 
to treat refractory epilepsy, appears to induce alterations in the microbiota which are necessary for 208 
its anti-seizure effects [54]. Together with the FODMAP diet for control of IBS symptoms [55], 209 
this is an example of a diet of reduced diversity which would not normally be considered beneficial 210 
for our gut microbes but which produce symptomatic improvements in the host. According to our 211 
current knowledge of the gut microbiota and host-microbe interactions within the framework of 212 
pharmacokinetics and pharmacodynamics, the effects of a wide range of host-directed xenobiotics 213 
on our bacteria community has to be more routinely considered in  drug development pipelines. 214 
Conclusion 215 
 216 
Recent research has aided substantially our efforts to make sense of the microbiome-gut-brain axis 217 
in gastrointestinal pharmacology and beyond. This includes advances over compositional surveys 218 
to important studies linking symptom severity to gut microbiome alterations in IBS, as well as 219 
landmark population based evidence linking gut microbiome signatures to depression and quality 220 
of life. Moreover, the increase in research linking the gut microbiome to neuropsychiatric disorders 221 
from clinical studies is supplemented with preclinical approaches that implicate the gut microbiome 222 
in regulating even the structure and activity of key brain regions. Meanwhile, traditional concepts 223 
in pharmacology will likely need to be redrawn to account for the reciprocal interactions between 224 
our gut microbes and xenobiotics. This will have important implications for pharmacodynamics 225 
and pharmacokinetic considerations during drug development. Our understanding of the molecular 226 
mediators underpinning host-microbe interactions now includes an appreciation that microbial 227 
metabolites can impact on specific receptors to influence aspects of host physiology such as 228 
gastrointestinal motility. It remains an appealing prospect that this knowledge can be harnessed 229 
effectively for therapeutic targeting of the microbiome to influence gut-brain axis signaling using 230 
interventions such as FMT, prebiotics, probiotics or postbiotics. Limiting the side effects associated 231 
with psychotropic drugs such as antipsychotics via microbiome-based approaches is a further 232 
avenue of investigation with high potential.  Effectively translating these promising recent 233 
advances into the prescription pads of the future is an ambitious but important research objective.  234 
Conflict of Interest 235 
10 
 
APC Microbiome Ireland collaborates with a number of industry partners including Dupont 236 
Nutrition Biosciences APS, Cremo SA, Alkermes Inc., 4D Pharma PLC, Mead Johnson Nutrition, 237 
Nutricia Danone and Suntory Wellness. GC has spoken at meetings sponsored by food and 238 
pharmaceutical companies including Janssen Ireland. This neither influenced nor constrained the 239 
content of this review. 240 
Acknowledgements 241 
APC Microbiome Ireland is a research centre funded by Science Foundation Ireland (SFI), through 242 
the Irish Government’s National Development Plan (grant no. 12/RC/2273). GC is supported by 243 
the Irish Health Research Board (Grant number ILP-POR-2017-013) and by the US Airforce Office 244 
of Scientific Research (Grant number FA9550-17-1-006).  245 
246 
11 
 
References and Recommended Reading 247 
* Of Special Interest 248 
** Of Outstanding Interest 249 
1. Sender R, Fuchs S, Milo R: Revised estimates for the number of human and bacteria cells 250 
in the body. PLoS Biol (2016) 14(8):e1002533. 251 
       252 
2. Sender R, Fuchs S, Milo R: Are we really vastly outnumbered? Revisiting the ratio of 253 
bacterial to host cells in humans. Cell (2016) 164(3):337-340. 254 
 255 
3. Falony G, Joossens M, Vieira-Silva S, Wang J, Darzi Y, Faust K, Kurilshikov A, Bonder MJ, 256 
Valles-Colomer M, Vandeputte D, Tito RY et al: Population-level analysis of gut 257 
microbiome variation. Science (2016) 352(6285):560-564. 258 
 259 
4. Vangay P, Johnson AJ, Ward TL, Al-Ghalith GA, Shields-Cutler RR, Hillmann BM, Lucas SK, 260 
Beura LK, Thompson EA, Till LM, Batres R et al: Us immigration westernizes the human 261 
gut microbiome. Cell (2018) 175(4):962-972 e910. 262 
 263 
5. Zhernakova A, Kurilshikov A, Bonder MJ, Tigchelaar EF, Schirmer M, Vatanen T, Mujagic Z, 264 
Vila AV, Falony G, Vieira-Silva S, Wang J et al: Population-based metagenomics analysis 265 
reveals markers for gut microbiome composition and diversity. Science (2016) 266 
352(6285):565-569. 267 
 268 
6. * Pasolli E, Asnicar F, Manara S, Zolfo M, Karcher N, Armanini F, Beghini F, Manghi P, Tett 269 
A, Ghensi P, Collado MC et al: Extensive unexplored human microbiome diversity 270 
revealed by over 150,000 genomes from metagenomes spanning age, geography, and 271 
lifestyle. Cell (2019) 176(3):649-662 e620. * This revealed the presence of new microbial species on or in 272 
the host, including the gut, associated with westernized or non-westernized lifestyles. 273 
 274 
7. Nayfach S, Shi ZJ, Seshadri R, Pollard KS, Kyrpides N: Novel insights from uncultivated 275 
genomes of the global human gut microbiome. Nature (2019). 276 
 277 
8. *Tap J, Derrien M, Tornblom H, Brazeilles R, Cools-Portier S, Dore J, Storsrud S, Le Neve B, 278 
Ohman L, Simren M: Identification of an intestinal microbiota signature associated with 279 
severity of irritable bowel syndrome. Gastroenterology (2017) 152(1):111-123 e118. * Important 280 
demonstration that alterations in the gut microbiota composition in irritable bowel syndrome are associated with 281 
symptom severity 282 
 283 
9. Hand TW, Vujkovic-Cvijin I, Ridaura VK, Belkaid Y: Linking the microbiota, chronic 284 
disease, and the immune system. Trends Endocrinol Metab (2016) 27(12):831-843. 285 
 286 
10. Harach T, Marungruang N, Duthilleul N, Cheatham V, Mc Coy KD, Frisoni G, Neher JJ, Fak 287 
F, Jucker M, Lasser T, Bolmont T: Reduction of abeta amyloid pathology in appps1 288 
transgenic mice in the absence of gut microbiota. Sci Rep (2017) 7(41802. 289 
 290 
11. Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, Challis C, Schretter 291 
CE, Rocha S, Gradinaru V, Chesselet MF et al: Gut microbiota regulate motor deficits and 292 
neuroinflammation in a model of parkinson's disease. Cell (2016) 167(6):1469-1480 e1412. 293 
 294 
12 
 
12. Scheperjans F, Aho V, Pereira PA, Koskinen K, Paulin L, Pekkonen E, Haapaniemi E, 295 
Kaakkola S, Eerola-Rautio J, Pohja M, Kinnunen E et al: Gut microbiota are related to 296 
parkinson's disease and clinical phenotype. Mov Disord (2015) 30(3):350-358. 297 
 298 
13. Wang M, Zhou J, He F, Cai C, Wang H, Wang Y, Lin Y, Rong H, Cheng G, Xu R, Zhou W: 299 
Alteration of gut microbiota-associated epitopes in children with autism spectrum 300 
disorders. Brain Behav Immun (2019) 75(192-199. 301 
 302 
14. Zheng P, Zeng B, Liu M, Chen J, Pan J, Han Y, Liu Y, Cheng K, Zhou C, Wang H, Zhou X 303 
et al: The gut microbiome from patients with schizophrenia modulates the glutamate-304 
glutamine-gaba cycle and schizophrenia-relevant behaviors in mice. Sci Adv (2019) 305 
5(2):eaau8317. 306 
 307 
15. Kelly JR, Borre Y, C OB, Patterson E, El Aidy S, Deane J, Kennedy PJ, Beers S, Scott K, 308 
Moloney G, Hoban AE et al: Transferring the blues: Depression-associated gut 309 
microbiota induces neurobehavioural changes in the rat. J Psychiatr Res (2016) 82(109-118. 310 
 311 
16. De Palma G, Lynch MD, Lu J, Dang VT, Deng Y, Jury J, Umeh G, Miranda PM, Pigrau Pastor 312 
M, Sidani S, Pinto-Sanchez MI et al: Transplantation of fecal microbiota from patients 313 
with irritable bowel syndrome alters gut function and behavior in recipient mice. Sci 314 
Transl Med (2017) 9(379). 315 
 316 
17. **Valles-Colomer M, Falony G, Darzi Y, Tigchelaar EF, Wang J, Tito RY, Schiweck C, 317 
Kurilshikov A, Joossens M, Wijmenga C, Claes S et al: The neuroactive potential of the 318 
human gut microbiota in quality of life and depression. Nat Microbiol (2019). ** Population 319 
based evidence linking gut microbiome signatures to depression and quality of life 320 
 321 
18. Luczynski P, Tramullas M, Viola M, Shanahan F, Clarke G, O'Mahony S, Dinan TG, Cryan 322 
JF: Microbiota regulates visceral pain in the mouse. Elife (2017) 6( 323 
 324 
19. Crouzet L, Gaultier E, Del'Homme C, Cartier C, Delmas E, Dapoigny M, Fioramonti J, 325 
Bernalier-Donadille A: The hypersensitivity to colonic distension of ibs patients can be 326 
transferred to rats through their fecal microbiota. Neurogastroenterol Motil (2013) 25(4):e272-327 
282. 328 
 329 
20. Clarke G, Grenham S, Scully P, Fitzgerald P, Moloney RD, Shanahan F, Dinan TG, Cryan JF: 330 
The microbiome-gut-brain axis during early life regulates the hippocampal 331 
serotonergic system in a sex-dependent manner. Mol Psychiatry (2013) 18(6):666-673. 332 
 333 
21. Moloney GM, O'Leary OF, Salvo-Romero E, Desbonnet L, Shanahan F, Dinan TG, Clarke 334 
G, Cryan JF: Microbial regulation of hippocampal mirna expression: Implications for 335 
transcription of kynurenine pathway enzymes. Behav Brain Res (2017) 334(50-54. 336 
 337 
22. * Hoban AE, Stilling RM, G MM, Moloney RD, Shanahan F, Dinan TG, Cryan JF, Clarke G: 338 
Microbial regulation of microrna expression in the amygdala and prefrontal cortex. 339 
Microbiome (2017) 5(1):102. * This study implicates the gut microbiome in appropriate regulation of 340 
microRNA in specific brain regions of importance in psychiatry 341 
 342 
13 
 
23. Chen JJ, Zeng BH, Li WW, Zhou CJ, Fan SH, Cheng K, Zeng L, Zheng P, Fang L, Wei H, 343 
Xie P: Effects of gut microbiota on the microrna and mrna expression in the 344 
hippocampus of mice. Behav Brain Res (2017) 322(Pt A):34-41. 345 
 346 
24. Cowan CSM, Hoban AE, Ventura-Silva AP, Dinan TG, Clarke G, Cryan JF: Gutsy moves: 347 
The amygdala as a critical node in microbiota to brain signaling. Bioessays (2018) 40(1). 348 
 349 
25. * Hoban AE, Stilling RM, Moloney G, Shanahan F, Dinan TG, Clarke G, Cryan JF: The 350 
microbiome regulates amygdala-dependent fear recall. Mol Psychiatry (2018) 23(5):1134-351 
1144. * This study implicates the gut microbiome in the brain-region specific control of fear recall 352 
 353 
26. Stilling RM, Moloney GM, Ryan FJ, Hoban AE, Bastiaanssen TF, Shanahan F, Clarke G, 354 
Claesson MJ, Dinan TG, Cryan JF: Social interaction-induced activation of rna splicing 355 
in the amygdala of microbiome-deficient mice. Elife (2018) 7( 356 
 357 
27. Stilling RM, Ryan FJ, Hoban AE, Shanahan F, Clarke G, Claesson MJ, Dinan TG, Cryan JF: 358 
Microbes & neurodevelopment--absence of microbiota during early life increases 359 
activity-related transcriptional pathways in the amygdala. Brain Behav Immun (2015) 360 
50(209-220. 361 
 362 
28. Horne R, St Pierre J, Odeh S, Surette M, Foster JA: Microbe and host interaction in 363 
gastrointestinal homeostasis. Psychopharmacology (Berl) (2019). 364 
 365 
29. ** Liu S, da Cunha AP, Rezende RM, Cialic R, Wei Z, Bry L, Comstock LE, Gandhi R, Weiner 366 
HL: The host shapes the gut microbiota via fecal microrna. Cell Host Microbe (2016) 367 
19(1):32-43. ** Important demonstration of interactions between host microrna and gut microbes 368 
 369 
30. Teng Y, Ren Y, Sayed M, Hu X, Lei C, Kumar A, Hutchins E, Mu J, Deng Z, Luo C, Sundaram 370 
K et al: Plant-derived exosomal micrornas shape the gut microbiota. Cell Host Microbe 371 
(2018) 24(5):637-652 e638. 372 
 373 
31. Moloney GM, Viola MF, Hoban AE, Dinan TG, Cryan JF: Faecal micrornas: Indicators of 374 
imbalance at the host-microbe interface? Benef Microbes (2018) 9(2):175-183. 375 
 376 
32. Golubeva AV, Joyce SA, Moloney G, Burokas A, Sherwin E, Arboleya S, Flynn I, Khochanskiy 377 
D, Moya-Perez A, Peterson V, Rea K et al: Microbiota-related changes in bile acid & 378 
tryptophan metabolism are associated with gastrointestinal dysfunction in a mouse 379 
model of autism. Ebiomedicine (2017) 24(166-178. 380 
 381 
33. ** Burokas A, Arboleya S, Moloney RD, Peterson VL, Murphy K, Clarke G, Stanton C, Dinan 382 
TG, Cryan JF: Targeting the microbiota-gut-brain axis: Prebiotics have anxiolytic and 383 
antidepressant-like effects and reverse the impact of chronic stress in mice. Biol Psychiatry 384 
(2017) 82(7):472-487. ** Demonstrates that prebiotics may also have potential in the treatment of stress-385 
related behavioural alterations 386 
 387 
34. Cohen LJ, Esterhazy D, Kim SH, Lemetre C, Aguilar RR, Gordon EA, Pickard AJ, Cross JR, 388 
Emiliano AB, Han SM, Chu J et al: Commensal bacteria make gpcr ligands that mimic 389 
human signalling molecules (vol 549, pg 48, 2017). Nature (2018) 556(7699):135-135. 390 
 391 
14 
 
35. Cryan JF, Clarke G, Dinan TG, Schellekens H: A microbial drugstore for motility. Cell Host 392 
Microbe (2018) 23(6):691-692. 393 
 394 
36. Bhattarai Y, Schmidt BA, Linden DR, Larson ED, Grover M, Beyder A, Farrugia G, Kashyap 395 
PC: Human-derived gut microbiota modulates colonic secretion in mice by regulating 396 
5-ht3 receptor expression via acetate production. Am J Physiol-Gastr L (2017) 313(1):G80-397 
G87.  398 
 399 
37. ** Bhattarai Y, Williams BB, Battaglioli EJ, Whitaker WR, Till L, Grover M, Linden DR, Akiba 400 
Y, Kandimalla KK, Zachos NC, Kaunitz JD et al: Gut microbiota-produced tryptamine 401 
activates an epithelial g-protein-coupled receptor to increase colonic secretion. Cell Host 402 
& Microbe (2018) 23(6):775-+. ** Confirms that a microbial metabolite can activate a host receptor to 403 
modulate gut function 404 
 405 
38. *Natividad JM, Agus A, Planchais J, Lamas B, Jarry AC, Martin R, Michel ML, Chong-Nguyen 406 
C, Roussel R, Straube M, Jegou S et al: Impaired aryl hydrocarbon receptor ligand 407 
production by the gut microbiota is a key factor in metabolic syndrome. Cell Metab (2018) 408 
28(5):737-+. * This study links bacterial metabolites to metabolic syndrome via activation a 409 
specific host receptor 410 
 411 
39. Lamas B, Richard ML, Leducq V, Pham HP, Michel ML, Da Costa G, Bridonneau C, Jegou S, 412 
Hoffmann TW, Natividad JM, Brot L et al: Card9 impacts colitis by altering gut microbiota 413 
metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med (2016) 414 
22(6):598-605. 415 
 416 
40. van de Wouw M, Boehme M, Lyte JM, Wiley N, Strain C, O'Sullivan O, Clarke G, Stanton C, 417 
Dinan TG, Cryan JF: Short-chain fatty acids: Microbial metabolites that alleviate stress-418 
induced brain-gut axis alterations. J Physiol-London (2018) 596(20):4923-4944. 419 
 420 
41. *Arentsen T, Qian Y, Gkotzis S, Femenia T, Wang T, Udekwu K, Forssberg H, Heijtz RD: 421 
The bacterial peptidoglycan-sensing molecule pglyrp2 modulates brain development 422 
and behavior. Mol Psychiatr (2017) 22(2):257-266. * Highlights a specific mechanism through which the 423 
gut microbiota modulates brain development and behavior 424 
 425 
42. Flannigan KL, Taylor MR, Pereira SK, Rodriguez-Arguello J, Moffat AW, Alston L, Wang 426 
XM, Poon KK, Beck PL, Rioux KP, Jonnalagadda M et al: An intact microbiota is required 427 
for the gastrointestinal toxicity of the immunosuppressant mycophenolate mofetil. J 428 
Heart Lung Transpl (2018) 37(9):1047-1059. 429 
 430 
43. ** van Kessel SP, Frye AK, El-Gendy AO, Castejon M, Keshavarzian A, van Dijk G, El Aidy 431 
S: Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of 432 
parkinson's disease. Nat Commun (2019) 10(1):310. ** Important demonstration that of the role of 433 
microbial metabolism in drug availability 434 
 435 
44. Guo YK, Crnkovic CM, Won KJ, Yang XT, Lee JR, Orjala J, Lee H, Jeong H: Commensal 436 
gut bacteria convert the immunosuppressant tacrolimus to less potent metabolites. 437 
Drug Metab Dispos (2019) 47(3):194-202. 438 
 439 
15 
 
45. Kumar K, Dhoke GV, Sharma AK, Jaiswal SK, Sharma VK: Mechanistic elucidation of 440 
amphetamine metabolism by tyramine oxidase from human gut microbiota using 441 
molecular dynamics simulations. J Cell Biochem (2019). 442 
 443 
46. Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL: Separating host 444 
and microbiome contributions to drug pharmacokinetics and toxicity. Science (2019) 445 
363(6427). 446 
 447 
47. ** Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, 448 
Fernandez KC, Dose H, Mori H, Patil KR et al: Extensive impact of non-antibiotic drugs 449 
on human gut bacteria. Nature (2018) 555(7698):623-628. ** Demonstrates the extent to which 450 
non-antibiotic host-directed drugs impact on bacterial growth and gut microbiome composition 451 
 452 
48. Cussotto S, Strain CR, Fouhy F, Strain RG, Peterson VL, Clarke G, Stanton C, Dinan TG, 453 
Cryan JF: Differential effects of psychotropic drugs on microbiome composition and 454 
gastrointestinal function. Psychopharmacology (Berl) (2018). 455 
 456 
49. Lyte M, Daniels KM, Schmitz-Esser S: Fluoxetine-induced alteration of murine gut 457 
microbial community structure: Evidence for a microbial endocrinology-based 458 
mechanism of action responsible for fluoxetine-induced side effects. PeerJ (2019) 459 
7(e6199. 460 
 461 
50. Davey KJ, O'Mahony SM, Schellekens H, O'Sullivan O, Bienenstock J, Cotter PD, Dinan TG, 462 
Cryan JF: Gender-dependent consequences of chronic olanzapine in the rat: Effects on 463 
body weight, inflammatory, metabolic and microbiota parameters. Psychopharmacology 464 
(2012) 221(1):155-169. 465 
 466 
51. Davey KJ, Cotter PD, O'Sullivan O, Crispie F, Dinan TG, Cryan JF, O'Mahony SM: 467 
Antipsychotics and the gut microbiome: Olanzapine-induced metabolic dysfunction is 468 
attenuated by antibiotic administration in the rat. Transl Psychiat (2013) 3( 469 
 470 
52. Morgan AP, Crowley JJ, Nonneman RJ, Quackenbush CR, Miller CN, Ryan AK, Bogue MA, 471 
Paredes SH, Yourstone S, Carroll IM, Kawula TH et al: The antipsychotic olanzapine 472 
interacts with the gut microbiome to cause weight gain in mouse. PLoS One (2014) 473 
9(12):e115225. 474 
 475 
53. Kao AC, Spitzer S, Anthony DC, Lennox B, Burnet PWJ: Prebiotic attenuation of 476 
olanzapine-induced weight gain in rats: Analysis of central and peripheral biomarkers 477 
and gut microbiota. Transl Psychiatry (2018) 8(1):66. 478 
 479 
54. * Olson CA, Vuong HE, Yano JM, Liang QY, Nusbaum DJ, Hsiao EY: The gut microbiota 480 
mediates the anti-seizure effects of the ketogenic diet. Cell (2018) 174(2):497. * Links this 481 
the gut microbiota seizure susceptibility  482 
 483 
55. Whelan K, Martin LD, Staudacher HM, Lomer MCE: The low fodmap diet in the 484 
management of irritable bowel syndrome: An evidence-based review of fodmap 485 
restriction, reintroduction and personalisation in clinical practice. J Hum Nutr Diet (2018) 486 
31(2):239-255. 487 
 488 
16 
 
56. Klünemann M: Human gut bacteria interactions with host-targeted drugs. In: The Faculty 489 
of Bio Sciences. PhD Thesis. University of Heidelberg,  (2018). 490 
 491 
 492 
 493 
 494 
  495 
17 
 
Figure Legends 496 
 497 
Figure 1: The Microbiome-gut-brain axis and Psychiatry 498 
 499 
The composition of the gut microbiome is under the influence of various intrinsic and extrinsic 500 
factors, such as the host genetics, age, and other lifestyle factors. The gut microbiome can recruit 501 
the gut-brain axis, a bidirectional communication system between the brain and the gut, to influence 502 
brain function and behaviour.  Alterations in the composition and function of the gut microbiome 503 
have been associated with a number of clinical psychiatric and neurological disorders while 504 
preclinical approaches confirm the capacity of our gut microbes to exert behavioural and functional 505 
effects of relevance to these brain disorders. Psychological stress exposure can also impact on the 506 
structure and function of the gut microbiome. 507 
 508 
Figure 2: Xenobiotics and Gut Microbiota Interactions 509 
 510 
Orally administrated drugs are, after ingestion, in direct contact with the gut microbiome. The co-511 
localization of bacteria and xenobiotics may result in reciprocal interactions. On one hand, many 512 
xenobiotics have antimicrobial properties and can alter microbiota composition, diversity and 513 
function, often in a manner that can be linked to the side effects of various medications. On the 514 
other hand, the gut microbiota can metabolize the ingested drugs or indirectly alter their 515 
metabolism by the host and this can result modification of availability, efficacy or toxicity of the 516 
drug in the organism. Many disease states are also associated with gut microbiome alterations, even 517 
prior to drug use although the implication of this are currently unclear. 518 
  519 
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Table 1: Psychotropic drugs and their effects on the gut microbiome and intestinal physiology 520 
in preclinical studies 521 
 522 
Drug Disease Observed effects Reference 
Aripiprazole 
Schizophrenia, major 
depression, bipolar disorder, 
obsessive- compulsive 
disorder 
 bacterial richness and diversity 
[48] 
 Firmicutes 
 the levels of acetate and isovalerate  
 distal ileum permeability 
 Coli   L gasseri  [56] 
Escitalopram Depression/anxiety disorders 
 Coli growth invitro  
[48] 
 distal ileum permeability 
Fluoxetine Depression/anxiety disorders 
Inhibit L. rhamnosus and E. Coli growth 
[48]  Deferribacteraceae 
 distal ileum permeability 
 Firmicute/Bacteroidete ratio [49] 
Lithium 
Bipolar disorder, mood-
stabilizer, major depression, 
schizophrenia 
 bacterial richness and diversity 
[48] 
 Actinobacteria et diminution Bacteroidetes 
Olanzapine 
Schizophrenia, bipolar 
disorder 
 level of Firmicute and  bacterial diversity in females 
[50]   Proteobacteria in males 
 Bacteroidetes 
 Firmicutes and  Bacteroidetes [51] 
 E. Coli and Enterococcus faecalis croissance in vitro [52] 
Valproate 
Epilepsy, bipolar disorder, 
schizophrenia 
 bacterial richness and diversity 
[48] 
 Actinobacteria and Firmicute -  Bacteroidete 
 propionate and butyrate levels and  isovalerate 
Venlafaxine Depressive/anxiety disorders  distal ileum permeability [48] 
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